. 2018 Feb 19;41(1):154–166. doi: 10.1590/1678-4685-GMB-2017-0091

Table 2. Results of the micronucleus assay related to the ability of IR-01 to cause or prevent chromosomal damage.

Experimental groups	Mean ± SE			%DR
	24 h	48 h	72 h	24 h	48 h	72 h
LOT 1
NC	3.0 ± 0.44	1.8 ± 0.20	0.6 ± 0.24	-	-	-
IR-01 12 mg/kg	3.8 ± 0.37^a	3.0 ± 0.31ª^*	4.2 ± 0.37ª^*	-	-	-
IR-01 24 mg/kg	4.2 ± 0.20^a	4.6 ± 0.60ª^*	4.8 ± 0.37ª^*	-	-	-
IR-01 48 mg/kg	4.8 ± 0.37ª^*	3.4 ± 0.50ª^*	5.2 ± 0.66ª^*	-	-	-
LOT 2
DOX	52 ± 2.56^a*	36 ± 1.72^a*	26 ± 1.16ª^*	-	-	-
+ IR-01 12 mg/kg	7.20.58^b*	5.2 ± 0.37^b*	7.2 ± 0.86^b*	91.43	90.06	74.01
+ IR-01 24 mg/kg	12 ± 0.70^b*	6.4 ± 0.50^b*	7.2 ± 0.37^b*	81.63	86.55	74.01
+ IR-01 48 mg/kg	13 ± 1.06^b*	9.4 ± 0.40^b*	9.4 ± 0.60^b*	79.59	77.78	65.35
LOT 3
CIS	27 ± 0.50ª^*	20 ± 0.55^a*	15 ± 0.50ª^*	-	-	-
+ IR-01 12 mg/kg	6.2 ± 0.37^c*	5.6 ± 0.24^c*	4.2 ± 0.20^c*	86.67	79.12	75.00
+ IR-01 24 mg/kg	7.0 ± 0.37^c*	7.6 ± 0.50^c*	6 ± 0.31^c*	83.33	68.14	62.50
+ IR-01 48 mg/kg	8.4 ± 0.50^c*	7.4 ± 0.60^c*	5.8 ± 0.37^c*	77.50	69.23	63.89
LOT 4
CPP	41 ± 2.17^a*	50 ± 2.34^a*	28 ± 2.80^a*	-	-	-
+ IR-01 12 mg/kg	33 ± 2.71^d	63 ± 3.75^d	24 ± 2.16^d	21.05	-26.97	14.60
+ IR-01 24 mg/kg	55 ± 3.63^d*	77 ± 2.95^d*	42 ± 3.88^d*	-36.84	-56.02	-51.10
+ IR-01 48 mg/kg	42 ± 3.85^d	71 ± 2.70^d	28 ± 2.10^d	-2.63	-43.57	00.00

SE: Standard error of the mean; %DR: Percent damage reduction; NC: Negative control group; DOX: Doxorubicin group; CIS: Cisplatin group; CPP: Cyclophosphamide group. ^(a)Statistically compared to the NC group; ^(b)Statistically compared to the DOX group; ^(c)Statistically compared to the CIS group; ^(d)Statistically compared to the CPP group; ^*statistically different (p < 0.05; Mann-Whitney test).